Why the study?
Does the 2017 hypertension guideline reduce major CVD events and all-cause mortality compared to the 2014 guideline in US adults?
Does the 2017 hypertension guideline reduce major CVD events and all-cause mortality compared to the 2014 guideline in US adults?
Implementation of the 2017 hypertension guidelines in the US is estimated to prevent more CVD events and deaths than the 2014 guidelines, though with a potential increase in adverse events.
Answers are grounded in this paper and cite their sources.
May support broader 2017 guideline implementation; leaves open net benefit versus harms in randomized trials.
Compared with the 2014 hypertension guideline, the 2017 hypertension guideline was associated with an increase in the proportion of adults recommended for antihypertensive treatment and a further reduction in major CVD events and all-cause mortality, but a possible increase in the number of adverse events in the United States.
No takes yet. Share an insight, caveat, or question.
Bundy et al. (2018) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: